Non-invasive Cancer Diagnostics Market Will Grow Rapidly In Coming Years

The global non-invasive cancer diagnostics market is expanding as healthcare systems increasingly prioritize early cancer detection, accurate diagnosis, and patient-friendly testing methods. Non-invasive diagnostics can identify cancer-related biomarkers and molecular changes using blood, urine, saliva, stool, imaging, and other biological samples without requiring traditional surgical biopsies. Growing cancer incidence, increasing awareness of early screening, advances in molecular diagnostics, and rising investment in precision medicine are creating significant opportunities for market participants.

According to Grand View Research, the global non-invasive cancer diagnostics market was valued at USD 4.8 billion in 2025 and is projected to reach USD 9.7 billion by 2033, registering a CAGR of 9.2% from 2026 to 2033. Increasing adoption of liquid biopsy technologies and growing demand for minimally invasive diagnostic approaches are expected to remain important contributors to market expansion.

Market Size and Growth Forecasts

The non-invasive cancer diagnostics market is expected to experience strong growth throughout the forecast period as conventional cancer diagnostic procedures are increasingly complemented by molecular and biomarker-based testing.

Cancer remains one of the leading causes of mortality worldwide, creating substantial demand for screening and early detection technologies. Detecting cancer at an earlier stage can provide opportunities for more timely treatment and improved disease management.

Liquid biopsy is becoming particularly important because it can identify circulating tumor DNA, circulating tumor cells, and other cancer-associated biomarkers from blood samples. The technology offers the potential for repeated testing and monitoring without requiring invasive tissue collection.

Increasing investments by pharmaceutical companies, biotechnology firms, diagnostic laboratories, and research institutions are also supporting the development of next-generation cancer diagnostics.

Download a free sample copy of the Non-invasive Cancer Diagnostics market report to understand detailed coverage and inclusions in the final report

Key Technologies

Several advanced technologies are shaping the non-invasive cancer diagnostics market.

Liquid biopsy is one of the most important technologies in the industry. It analyzes biological materials circulating in the bloodstream to detect cancer-related genetic and molecular information. Applications include early cancer detection, treatment selection, disease monitoring, and identification of treatment resistance.

Next-generation sequencing, or NGS, enables researchers and clinicians to analyze genetic alterations associated with tumors. NGS can support comprehensive molecular profiling and help identify biomarkers that may guide targeted therapies.

Polymerase chain reaction, or PCR, is another important technology used to detect specific genetic sequences and cancer-associated molecular markers.

Imaging technologies also contribute significantly to non-invasive cancer diagnostics. Magnetic resonance imaging, computed tomography, positron emission tomography, and ultrasound can help identify tumors, assess disease progression, and monitor treatment response.

Artificial intelligence is increasingly being integrated with medical imaging and molecular diagnostic platforms. AI-based systems can assist with image interpretation, pattern recognition, risk assessment, and identification of subtle abnormalities.

Market Segmentation & Performance

The market can be segmented based on technology, application, cancer type, end use, and region.

• Liquid biopsy represents one of the most attractive segments due to its broad potential across cancer screening, diagnosis, treatment monitoring, and recurrence detection. Continued research into circulating tumor DNA and other biomarkers is expected to strengthen the commercial potential of liquid biopsy solutions.
• Based on cancer type, lung cancer, breast cancer, colorectal cancer, prostate cancer, and other solid tumors represent important application areas. Increasing screening programs and the growing prevalence of these cancers are creating demand for earlier and more convenient diagnostic solutions.
• Breast cancer diagnostics are benefiting from advances in molecular biomarkers and imaging technologies. Colorectal cancer testing is also gaining attention as healthcare systems expand screening initiatives.
• Lung cancer represents another important application because early-stage disease can be difficult to detect through conventional approaches. Molecular diagnostics and liquid biopsy technologies may provide additional tools for identifying disease-related biomarkers.
• Hospitals and diagnostic laboratories remain important end users. However, specialized diagnostic centers, research institutions, and pharmaceutical companies are increasingly adopting advanced non-invasive testing technologies.

Looking for more specific insights? Customize this report to suite your business needs

Regional Insights

North America represents a major regional market because of its advanced healthcare infrastructure, high cancer research expenditure, strong biotechnology industry, and early adoption of precision medicine technologies. The United States remains a key contributor due to significant investments in molecular diagnostics and oncology research.

Europe is another important market, supported by national cancer screening programs, healthcare modernization, and increasing adoption of advanced diagnostic technologies. Germany, the United Kingdom, France, Italy, and Spain are among the major markets contributing to regional demand.

Asia Pacific is expected to provide significant growth opportunities during the forecast period. Rising cancer incidence, improving healthcare infrastructure, increasing healthcare expenditure, and growing awareness of early diagnosis are supporting demand across China, Japan, India, South Korea, and Australia.

China is investing heavily in biotechnology and precision medicine, while Japan has a mature healthcare system with increasing interest in advanced molecular diagnostics. India is also witnessing greater adoption of sophisticated diagnostic services as healthcare accessibility improves.

Latin America is gradually expanding as cancer screening programs and diagnostic infrastructure improve. The Middle East and Africa are also expected to experience increasing demand as governments strengthen oncology services and invest in healthcare modernization.

Key Market Players

The global non-invasive cancer diagnostics market includes established diagnostic companies, biotechnology firms, molecular testing companies, and technology providers.

Major industry participants include:

• Guardant Health, Inc.
• Natera, Inc.
• Exact Sciences Corporation
• Foundation Medicine, Inc.
• GRAIL, LLC
• F. Hoffmann-La Roche Ltd.
• Illumina, Inc.
• Thermo Fisher Scientific Inc.
• QIAGEN N.V.
• Bio-Rad Laboratories, Inc.
• Danaher Corporation
• Abbott Laboratories
• Siemens Healthineers
• Becton, Dickinson and Company
• NeoGenomics Laboratories

Explore our dedicated business services:

• US Healthcare Facility Mapping & Intelligence Portal – Claims analytics (MS-DRG, service lines, ICD-10 outpatient, APC reimbursement, CPT-level) plus hospital-level financials (balance sheet, income statement, uncompensated care, financial health dashboards), covering 25,000+ healthcare facilities — including 7,000+ hospitals, independent pharmacies, freestanding EDs, concierge physicians, and ASCs.
• Brainshare Consulting – End-to-end business consulting services including Opportunity assessment, GTM support, Competitive intelligence, and Consumer Analytics.
• Custom Research – Get a market intelligence report tailored to your specific requirements and aligned with your business goals.
• Consumer Insights – Capture real, evolving consumer sentiment and behavior to help you make data driven strategies.
• Horizon Databooks – Access the world’s largest portal of Market Reports & Statistics
• Investment Insights – Make investment decisions with data driven insights, powered by domain and technology
• Signal (Pricing Intelligence) - Commodity price intelligence to drives strategic advantage.

About us:
Grand View Research, a market research and consulting company, provides syndicated research reports, customized research reports, and consulting services. Grand View Research database is used by the world's renowned academic institutions and Fortune 500 companies to understand the global and regional business environment. Our database features thousands of statistics and in-depth analysis on 46 industries in 25 major countries worldwide.